Company patents
INTERVET INC.
Intervet Inc. demonstrates a strong focus on Pharmaceutical Preparations (63.8% of portfolio) and Therapeutic Activity (Pharma) (57.6%), with a surprising surge in Heterocyclic Compounds (Pharma) in 2024, growing by 233.3% YoY, indicating a past emerging focus in this area, although patenting activity across most categories, including Animal Husbandry / Fishing, has seen significant declines in 2025 and so far in 2026.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
177 US filings (since 2023) · 11 categories · 20 themes
Methods and compositions for monitoring the physiological state of animals, diagnosing diseases, and administering therapeutic interventions.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Specialized tools and structures for raising aquatic organisms or for catching fish, including platforms, bait dispensers, and reels.
Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.
Methods and intermediates for preparing complex organic molecules intended as active pharmaceutical ingredients (APIs), often involving multi-step synthesis and optimization of reaction pathways.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Innovation in chemical compounds or optimized formulations specifically designed to control or inhibit the growth of unwanted plants (weeds) in agricultural settings, often with improved selectivity or reduced environmental impact.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Methods and apparatus for the efficient and selective production of organic compounds, including amines, acids, and esters, often involving catalytic or continuous processes and purification steps.
Mechanical or electromechanical systems designed for precise, often self-administered, delivery of medicaments, including features for dose setting, needle insertion/retraction, and safety mechanisms to prevent premature activation.
Development and application of living organisms (e.g., bacteria, fungi, viruses) or their natural derivatives (e.g., peptides, plant extracts) as agents to suppress or eliminate agricultural pests, weeds, or plant diseases.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.
Development and use of animal subjects, often genetically modified, to study human diseases, test treatments, or understand biological processes.
Technologies focused on enhancing the stability, efficacy, spread, or targeted application of biocidal active ingredients through specialized carriers, adjuvants, encapsulation, or physical forms (e.g., gels, spray-dried particles).
Patents
Showing 1-7 of 7
Automated Injector Mechanisms